.jpg)
.jpg)
.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Antibiotic overuse is a key driver in the rise of antimicrobial resistance (AMR)...
Two new studies led by researchers at Washington University School of Medicine i...
As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Lea...
Demand for weight-loss medications sold under brand names such as Ozempic and We...
Researchers at Karolinska Institutet and the Astrid Lindgren Children's Hospital...
A collaborative study between researchers from the Yong Loo Lin School of Medici...
A team of scientists has developed a groundbreaking approach using specially des...
A natural compound derived from gut-friendly bacteria significantly slows the pr...
Basal cell carcinomas, the most common form of skin cancer, occur in chronically...
Antibiotic resistance is a global public health crisis responsible for more than...
Biomedical engineers at Duke University have developed an AI-based platform that...
Secondary prevention medications for cardiovascular diseases (CVD) are underused...
For the last 10 years, the only effective treatment for hypophosphatasia (HPP) h...
Tuberculosis is a serious global health threat that infected more than 10 millio...
Many people would like to delay or even stop the aging process. Previous clinica...
After combing through 4,000 existing medications, an artificial intelligence too...
Elsewhere, cell therapy developer Turnstone Biologics announced a second round o...
CagriSema, which underperformed expectations in its first Phase 3 test, will be ...
Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to ...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
That includes treating more than 200,000 patients with the irregular heartbeat k...
Glucotrack has cleared the first human clinical study of its long-term continuou...
X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as...
AstraZeneca has ended development of its oral factor D inhibitor vemircopan, tri...